{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:25:45Z","timestamp":1778275545256,"version":"3.51.4"},"reference-count":132,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1053\/j.semnuclmed.2025.02.013","type":"journal-article","created":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T11:59:27Z","timestamp":1741521567000},"page":"190-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Advances of PET\/CT in Target Delineation of Lung Cancer Before Radiation Therapy"],"prefix":"10.1053","volume":"55","author":[{"given":"Cedric","family":"Richlitzki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farkhad","family":"Manapov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-8438","authenticated-orcid":false,"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7085-4066","authenticated-orcid":false,"given":"Moritz","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf Alexander","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8238-1198","authenticated-orcid":false,"given":"Marcus","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3779-1398","authenticated-orcid":false,"given":"Chukwuka","family":"Eze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0001","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/j.semnuclmed.2022.05.003","article-title":"PET\/CT for target delineation of lung cancer before radiation therapy","volume":"52","author":"Manapov","year":"2022","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0002","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/nrc1451","article-title":"Radiation oncology: a century of achievements","volume":"4","author":"Bernier","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0003","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jtho.2019.10.002","article-title":"Three-year overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC","volume":"15","author":"Gray","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0004","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0005","doi-asserted-by":"crossref","first-page":"R363","DOI":"10.1088\/0031-9155\/51\/13\/R21","article-title":"IMRT: a review and preview","volume":"51","author":"Bortfeld","year":"2006","journal-title":"Phys Med Biol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0006","article-title":"The role of online MR-guided multi-fraction stereotactic ablative radiotherapy in lung tumours","volume":"45","author":"Hering","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0007","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13014-020-01519-1","article-title":"Recent advances of PET imaging in clinical radiation oncology","volume":"15","author":"Unterrainer","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0008","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1007\/s00259-021-05211-8","article-title":"PET\/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC-current state and future directions","volume":"48","author":"Eze","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0009","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0011","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","article-title":"Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin","volume":"16","author":"Oser","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0012","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3390\/cancers11071010","article-title":"Lung-seeking metastases","volume":"11","author":"Stella","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"Suppl 2","key":"10.1053\/j.semnuclmed.2025.02.013_bib0013","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/resp.13870","article-title":"Radiotherapy treatment for lung cancer: current status and future directions","volume":"25","author":"Vinod","year":"2020","journal-title":"Respirology"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0014","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0015","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jtho.2016.10.018","article-title":"Multi-institutional prospective study of reirradiation with Proton beam radiotherapy for locoregionally recurrent non-small cell lung cancer","volume":"12","author":"Chao","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0016","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3390\/cancers13071613","article-title":"Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC leads to significant improvement of local-regional control and overall survival in the real-world setting","volume":"13","author":"Taugner","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"Suppl 4","key":"10.1053\/j.semnuclmed.2025.02.013_bib0017","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0018","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"issue":"suppl_4","key":"10.1053\/j.semnuclmed.2025.02.013_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0020","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0021","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","article-title":"Treatment of oligometastatic non-small cell lung cancer: an ASTRO\/ESTRO clinical practice guideline","volume":"13","author":"Iyengar","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0022","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ijrobp.2011.06.2003","article-title":"Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer","volume":"83","author":"Lagerwaard","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0023","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2018.1251","article-title":"Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG Oncology RTOG 0618 trial","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0024","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3390\/cancers12040885","article-title":"Stereotactic radiotherapy for ultra-Central lung oligometastases in non-small-cell lung cancer","volume":"12","author":"Loi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0025","series-title":"Advances in Magnetic Resonance Technology and Applications","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/B978-0-323-91689-9.00013-3","article-title":"Chapter 13 - lung tumors","author":"Eze","year":"2023"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0026","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jamaoncol.2023.6033","article-title":"Accelerated hypofractionated chemoradiation followed by stereotactic ablative radiotherapy boost for locally advanced, unresectable non-small cell lung cancer: a nonrandomized controlled trial","volume":"10","author":"Wu","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0027","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jamaoncol.2023.5856","article-title":"Stereotactic body radiotherapy in locally advanced non-small cell lung cancer-is this the future?","volume":"10","author":"Lester-Coll","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0028","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(24)00573-4","article-title":"Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial","volume":"26","author":"Heinzerling","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0029","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG Oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without Cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0031","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0032","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/88.17.1210","article-title":"Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial","volume":"88","author":"Dillman","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0033","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fonc.2011.00047","article-title":"Radiation dose escalation in stage III non-small-cell lung cancer","volume":"1","author":"Terakedis","year":"2011","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0034","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1001\/jamaoncol.2018.4833","article-title":"Redefining the role of prophylactic cranial irradiation in the modern era of active surveillance in small cell lung cancer","volume":"5","author":"Eze","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0035","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"issue":"Suppl 6","key":"10.1053\/j.semnuclmed.2025.02.013_bib0036","article-title":"Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Fr\u00fch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0037","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0038","first-page":"49","article-title":"Prophylactic cranial irradiation in small-cell lung cancer: update on patient selection, efficacy and outcomes","volume":"9","author":"Manapov","year":"2018","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0039","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ijrobp.2024.08.013","article-title":"Concurrent chemoradiation \u00b1 atezolizumab (atezo) in limited-stage small cell lung cancer (LS-SCLC): results of NRG Oncology\/Alliance LU005","volume":"120","author":"Higgins","year":"2024","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"issue":"5 Suppl","key":"10.1053\/j.semnuclmed.2025.02.013_bib0040","doi-asserted-by":"crossref","first-page":"e142S","DOI":"10.1378\/chest.12-2353","article-title":"Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: american College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Rivera","year":"2013","journal-title":"Chest."},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0041","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.21037\/tlcr-20-805","article-title":"Evolving target volume concepts in locally advanced non-small cell lung cancer","volume":"10","author":"Nestle","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","article-title":"ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer","volume":"127","author":"Nestle","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0043","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.radonc.2020.07.012","article-title":"ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer","volume":"152","author":"Le Pechoux","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0044","volume":"6","author":"Gkika","year":"2023"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0045","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/0284186X.2021.1941244","article-title":"Feasibility of hypofractionated radiotherapy in inoperable node-positive NSCLC patients with poor prognostic factors and limited pulmonary reserve: a prospective observational study","volume":"60","author":"Eze","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0046","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/cncr.34201","article-title":"Pooled analysis on image-guided moderately hypofractionated thoracic irradiation in inoperable node-positive\/recurrent patients with non-small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve","volume":"128","author":"Eze","year":"2022","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0047","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijrobp.2024.04.001","article-title":"Incorporation of functional lung imaging into radiation therapy planning in patients with lung cancer: a systematic review and meta-analysis","volume":"120","author":"Midroni","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0048","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2967\/jnumed.123.266965","article-title":"An (18)F-FDG PET\/CT and mean lung dose model to predict early radiation pneumonitis in stage III non-small cell lung cancer patients treated with chemoradiation and immunotherapy","volume":"65","author":"Thor","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0049","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1053\/j.semnuclmed.2018.10.013","article-title":"PET\/CT lung ventilation and perfusion scanning using galligas and gallium-68-MAA","volume":"49","author":"Le Roux","year":"2019","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.phro.2022.03.005","article-title":"Quantitative assessment of ventilation-perfusion relationships with gallium-68 positron emission tomography\/computed tomography imaging in lung cancer patients","volume":"22","author":"Li","year":"2022","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0051","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13014-023-02244-1","article-title":"Ventilation and perfusion MRI at a 0.35 T MR-linac: feasibility and reproducibility study","volume":"18","author":"Klaar","year":"2023","journal-title":"Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110468","article-title":"MRI-based ventilation and perfusion imaging to predict radiation-induced pneumonitis in lung tumor patients at a 0.35T MR-Linac","volume":"199","author":"Klaar","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0053","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2021.12.048","article-title":"Perspective paper about the joint EANM\/SNMMI\/ESTRO practice recommendations for the use of 2-[(18)F]FDG-PET\/CT external beam radiation treatment planning in lung cancer","volume":"168","author":"Vaz","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0054","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ijrobp.2023.11.005","article-title":"A glimpse into the future for unresectable stage III non-small cell lung cancer","volume":"118","author":"Bartolomeo","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0055","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1007\/s00259-021-05624-5","article-title":"Joint EANM\/SNMMI\/ESTRO practice recommendations for the use of 2-[(18)F]FDG PET\/CT external beam radiation treatment planning in lung cancer V1.0","volume":"49","author":"Vaz","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0056","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2217\/fon-2017-0465","article-title":"Biological imaging for individualized therapy in radiation oncology: part II medical and clinical aspects","volume":"14","author":"Gkika","year":"2018","journal-title":"Future Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0057","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.radonc.2015.03.014","article-title":"PET\/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014","volume":"116","author":"Konert","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0058","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijrobp.2005.06.034","article-title":"Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis","volume":"64","author":"Steenbakkers","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0059","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2017.02.011","article-title":"Positron emission tomography and computed tomographic imaging (PET\/CT) for dose planning purposes of thoracic radiation with curative intent in lung cancer patients: a systematic review and meta-analysis","volume":"123","author":"Hallqvist","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0060","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13014-016-0698-3","article-title":"Involved field radiotherapy (IFRT) versus elective nodal irradiation (ENI) for locally advanced non-small cell lung cancer: a meta-analysis of incidence of elective nodal failure (ENF)","volume":"11","author":"Li","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0061","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijrobp.2009.04.075","article-title":"Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study","volume":"77","author":"van Loon","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0062","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jtho.2018.09.021","article-title":"Toxicity related to radiotherapy dose and targeting strategy: a pooled analysis of Cooperative group trials of combined modality therapy for locally advanced non-small cell lung cancer","volume":"14","author":"Schild","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0063","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(24)00010-9","article-title":"Systematic endoscopic staging of mediastinum to guide radiotherapy planning in patients with locally advanced non-small-cell lung cancer (SEISMIC): an international, multicentre, single-arm, clinical trial","volume":"12","author":"Steinfort","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109505","article-title":"Feasibility of omitting the clinical target volume under PET-CT guidance in unresectable stage III non-small-cell lung cancer: a phase II clinical trial","volume":"181","author":"Cui","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0065","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(20)30013-9","article-title":"Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial","volume":"21","author":"Nestle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"17_suppl","key":"10.1053\/j.semnuclmed.2025.02.013_bib0066","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8069","article-title":"Overall survival following heterogeneous FDG-guided dose-escalation for locally advanced NSCLC in the international phase III NARLAL2 trial","volume":"42","author":"Schytte","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0067","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.radonc.2017.06.022","article-title":"Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): design and early dosimetric results of a randomized, multi-centre phase-III study","volume":"124","author":"M\u00f8ller","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0068","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S1470-2045(24)00320-6","article-title":"Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [(18)F]FDG-PET tumour residual uptake at 42 gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial","volume":"25","author":"Vera","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0069","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1200\/JCO.24.00022","article-title":"Primary results of NRG-RTOG1106\/ECOG-ACRIN 6697: a randomized phase II trial of individualized adaptive (chemo)radiotherapy using midtreatment (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography in stage III non-small cell lung cancer","volume":"42","author":"Kong","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.radonc.2012.03.005","article-title":"The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer","volume":"104","author":"van Elmpt","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109492","article-title":"(18)F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): results from a randomised clinical trial","volume":"181","author":"Cooke","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0072","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2018.09.019","article-title":"The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)","volume":"131","author":"van Diessen","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0073","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.23.00627","article-title":"Selective personalized RadioImmunotherapy for locally advanced non-small-cell lung cancer trial (SPRINT)","volume":"42","author":"Ohri","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2025.01.005","article-title":"Randomized evaluation of the PET-adjusted IMRT for NSCLC trial (REPAINT)","author":"Ohri","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0075","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO-24-01448","article-title":"Can we offset local recurrence in locally advanced non-small cell lung cancer? The merry-go-round of radiation dose escalation and stubborn outcomes","volume":"42","author":"Owen","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0076","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.radonc.2011.12.018","article-title":"Radiographic changes after lung stereotactic ablative radiotherapy (SABR)\u2013can we distinguish recurrence from fibrosis? A systematic review of the literature","volume":"102","author":"Huang","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0077","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.2214\/AJR.19.21227","article-title":"Lung cancer recurrence: (18)F-FDG PET\/CT in clinical practice","volume":"213","author":"Kandathil","year":"2019","journal-title":"AJR Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0078","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/JTO.0000000000000185","article-title":"Primary tumor standardized uptake value measured on F18-fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis","volume":"9","author":"Na","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2017.06.003","article-title":"European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer","volume":"124","author":"De Ruysscher","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0080","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1016\/S1470-2045(24)00529-1","article-title":"[(18)F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer","volume":"25","author":"Bowen Jones","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0081","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1088\/0031-9155\/52\/1\/017","article-title":"Population and patient-specific target margins for 4D adaptive radiotherapy to account for intra- and inter-fraction variation in lung tumour position","volume":"52","author":"Hugo","year":"2007","journal-title":"Phys Med Biol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0082","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijrobp.2006.12.024","article-title":"Interfractional variations in patient setup and anatomic change assessed by daily computed tomography","volume":"68","author":"Li","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0083","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s13566-013-0091-x","article-title":"Metabolic tumor volume on PET reduced more than gross tumor volume on CT during radiotherapy in patients with non-small cell lung cancer treated with 3DCRT or SBRT","volume":"2","author":"Mahasittiwat","year":"2013","journal-title":"J Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0084","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00259-017-3762-9","article-title":"Role of interim (18)F-FDG-PET\/CT for the early prediction of clinical outcomes of Non-small cell lung cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review","volume":"44","author":"Cremonesi","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0085","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1007\/s00259-023-06192-6","article-title":"Metabolic patterns on [(18)F]FDG PET\/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy\u2009\u00b1\u2009durvalumab maintenance treatment","volume":"50","author":"Holzgreve","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0086","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00259-021-05584-w","article-title":"Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy\u2009\u00b1\u2009immune checkpoint inhibition","volume":"49","author":"Unterrainer","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109728","article-title":"Pretreatment 18-FDG-PET\/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy","volume":"185","author":"Grambozov","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0088","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s41824-024-00220-w","article-title":"Prognostic significance of pretreatment PET parameters in inoperable, node-positive NSCLC patients with poor prognostic factors undergoing hypofractionated radiotherapy: a single-institution retrospective study","volume":"8","author":"Zinn","year":"2024","journal-title":"EJNMMI Rep"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0089","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00259-018-4063-7","article-title":"How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience","volume":"45","author":"Roengvoraphoj","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0090","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s13566-015-0184-9","article-title":"Metabolic response assessment with (18)F-FDG PET\/CT: inter-method comparison and prognostic significance for patients with non-small cell lung cancer","volume":"4","author":"Wang","year":"2015","journal-title":"J Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0091","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.radonc.2011.07.023","article-title":"Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC)","volume":"102","author":"Edet-Sanson","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0092","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00259-014-2687-9","article-title":"FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2)","volume":"41","author":"Vera","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0093","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jamaoncol.2017.0982","article-title":"Effect of midtreatment PET\/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: a phase 2 clinical trial","volume":"3","author":"Kong","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0094","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00066-021-01812-2","article-title":"Value of PET imaging for radiation therapy","volume":"197","author":"Lapa","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00066-017-1229-3","article-title":"Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer","volume":"194","author":"Roengvoraphoj","year":"2018","journal-title":"Strahlenther Onkol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0096","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.radonc.2017.11.023","article-title":"Serial 4DCT\/4DPET imaging to predict and monitor response for locally-advanced non-small cell lung cancer chemo-radiotherapy","volume":"126","author":"Bissonnette","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0097","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1007\/s00259-011-1838-5","article-title":"Standard uptake value and metabolic tumor volume of \u00b9\u2078F-FDG PET\/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer","volume":"38","author":"Huang","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0098","doi-asserted-by":"crossref","first-page":"e440","DOI":"10.1097\/RLU.0000000000003680","article-title":"Fully integrated quantitative multiparametric analysis of non-small cell lung cancer at 3-T PET\/MRI: toward one-stop-shop tumor biological characterization at the supervoxel level","volume":"46","author":"Besson","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0099","article-title":"Positron emission tomography\/magnetic resonance imaging radiomics in predicting lung adenocarcinoma and squamous cell carcinoma","volume":"12","author":"Tang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0100","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000349","article-title":"Predictive value of integrated (18)F-FDG PET\/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer","volume":"8","author":"Umeda","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0101","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00259-018-4109-x","article-title":"Prospective comparison of (18)F-FDG PET\/MRI and (18)F-FDG PET\/CT for thoracic staging of non-small cell lung cancer","volume":"46","author":"Kirchner","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0102","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1007\/s00330-016-4255-0","article-title":"Preoperative staging of non-small cell lung cancer: prospective comparison of PET\/MR and PET\/CT","volume":"26","author":"Lee","year":"2016","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0103","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00330-016-4397-0","article-title":"Thoracic staging with (18)F-FDG PET\/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to (18)F-FDG PET\/CT?","volume":"27","author":"Schaarschmidt","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0104","first-page":"106","article-title":"The technical design and concept of a PET\/CT linac for biology-guided radiotherapy","volume":"29","author":"Oderinde","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0105","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2023.12.019","article-title":"BIOGUIDE-X: a first-in-Human study of the performance of positron emission tomography-guided radiation therapy","volume":"118","author":"Vitzthum","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0106","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1002\/mp.17114","article-title":"Commissioning of a novel PET-Linac for biology-guided radiotherapy (BgRT)","volume":"51","author":"Surucu","year":"2024","journal-title":"Med Phys"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0107","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3413\/Nukmed-0452-11-12","article-title":"Multi-centre calibration of an adaptive thresholding method for PET-based delineation of tumour volumes in radiotherapy planning of lung cancer","volume":"51","author":"Schaefer","year":"2012","journal-title":"Nuklearmedizin"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0108","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1002\/mp.14030","article-title":"Strategies for effective physics plan and chart review in radiation therapy: report of AAPM Task Group 275","volume":"47","author":"Ford","year":"2020","journal-title":"Med Phys"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0109","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/RLU.0000000000002810","article-title":"A machine-learning approach using PET-based radiomics to predict the histological subtypes of lung cancer","volume":"44","author":"Hyun","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0110","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00259-020-04747-5","article-title":"Additional value of metabolic parameters to PET\/CT-based radiomics nomogram in predicting lymphovascular invasion and outcome in lung adenocarcinoma","volume":"48","author":"Nie","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0111","doi-asserted-by":"crossref","first-page":"814","DOI":"10.2967\/jnumed.119.228106","article-title":"Pretreatment (18)F-FDG PET\/CT radiomics predict local recurrence in patients treated with stereotactic body radiotherapy for early-stage non-small cell lung cancer: a multicentric study","volume":"61","author":"Dissaux","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0112","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1158\/1078-0432.CCR-18-3908","article-title":"Voxel Forecast for Precision oncology: predicting spatially variant and multiscale cancer therapy response on longitudinal quantitative molecular imaging","volume":"25","author":"Bowen","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"Suppl 21","key":"10.1053\/j.semnuclmed.2025.02.013_bib0113","doi-asserted-by":"crossref","first-page":"S2508","DOI":"10.21037\/jtd.2018.07.101","article-title":"The developing role of FDG PET imaging for prognostication and radiotherapy target volume delineation in non-small cell lung cancer","volume":"10","author":"Konert","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0114","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1038\/s41467-020-19116-x","article-title":"Non-invasive decision support for NSCLC treatment using PET\/CT radiomics","volume":"11","author":"Mu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0115","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00259-019-04592-1","article-title":"Value of pre-therapy (18)F-FDG PET\/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer","volume":"47","author":"Zhang","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0116","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002118","article-title":"Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET\/CT images","volume":"9","author":"Mu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0117","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1007\/s00259-019-04625-9","article-title":"Radiomics of (18)F-FDG PET\/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy","volume":"47","author":"Mu","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0118","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat Commun"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0119","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2967\/jnumed.121.262045","article-title":"First-in-humans evaluation of a PD-L1-binding peptide PET radiotracer in non-small cell lung cancer patients","volume":"63","author":"Zhou","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0120","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2967\/jnumed.114.153098","article-title":"PET imaging of abdominal aortic aneurysm with 64Cu-labeled anti-CD105 antibody fab fragment","volume":"56","author":"Shi","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0121","first-page":"686","article-title":"PD-L1 PET\/CT imaging with radiolabeled durvalumab in patients with advanced-stage non-small cell lung cancer","volume":"63","author":"Smit","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0122","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.annonc.2021.10.213","article-title":"(89)Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer","volume":"33","author":"Kok","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0123","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1021\/acs.molpharmaceut.2c00084","article-title":"(124)I-labeled monoclonal antibody and fragment for the noninvasive evaluation of tumor PD-L1 expression In vivo","volume":"19","author":"Cheng","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0124","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2214\/AJR.21.27246","article-title":"Editorial comment: evolving indications for FDG PET\/MRI in lung cancer","volume":"218","author":"Bennett","year":"2022","journal-title":"AJR Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0125","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2214\/AJR.21.26868","article-title":"Small cell lung cancer staging: prospective comparison of conventional staging tests, FDG PET\/CT, whole-body MRI, and coregistered FDG PET\/MRI","volume":"218","author":"Ohno","year":"2022","journal-title":"AJR Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0126","first-page":"48","article-title":"Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET). Npj","volume":"2","author":"Mori","year":"2024","journal-title":"Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0127","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1007\/s00259-019-04346-z","article-title":"FAPI-PET\/CT improves staging in a lung cancer patient with cerebral metastasis","volume":"46","author":"Giesel","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0128","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0129","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1007\/s00259-021-05297-0","article-title":"[(18)F]-C-SNAT4: an improved caspase-3-sensitive nanoaggregation PET tracer for imaging of tumor responses to chemo- and immunotherapies","volume":"48","author":"Chen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0130","doi-asserted-by":"crossref","first-page":"11239","DOI":"10.1038\/s41598-021-90662-0","article-title":"Multimodal evaluation of hypoxia in brain metastases of lung cancer and interest of hypoxia image-guided radiotherapy","volume":"11","author":"Corroyer-Dulmont","year":"2021","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0131","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.3390\/cancers13164101","article-title":"First comparison between [18f]-FMISO and [18f]-Faza for preoperative pet imaging of hypoxia in lung cancer","volume":"13","author":"Thureau","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.02.013_bib0132","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1007\/s00259-021-05672-x","article-title":"Preclinical and exploratory human studies of novel (68)Ga-labeled d-peptide antagonist for PET imaging of TIGIT expression in cancers","volume":"49","author":"Wang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T23:41:30Z","timestamp":1741909290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825000224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":132,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0001299825000224"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.02.013","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances of PET\/CT in Target Delineation of Lung Cancer Before Radiation Therapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}